We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Klinička iskustva u liječenju kronične boli tapentadolom.
- Authors
LEROTIĆ, SANJA BERIĆ; ŠKLEBAR, IVAN; ILIĆ, MAJA KARAMAN; KOŽUL, IDA; MLIČEVIĆ, MARIN
- Abstract
Tapentadol is a novel analgesic registered in slow-release form for medium-intensity and intense chronic pain, which targets both the nociceptive and neuropathic component of the pain signal. It utilizes two synergistic mechanisms: MOR - mu opioid receptor agonism and NRI - norepinephrine reuptake inhibition. The goal of this study was to compare the effectiveness of pain management and tolerability of tapentadol in our clinical experience with existing reports from abroad. The study included 92 patients from our pain management clinic who were prescribed slow-release tapentadol in doses of at least 50 mg twice daily. We tracked the effectiveness of pain management recorded using the visual analog scale, as well as the appearance and type of adverse effects. Further directions for dose adjustment or discontinuation of therapy were also recorded. In our experience, 66% of patients reported a satisfactory analgesic effect. The adverse effect rate was 43%; 54% of patients discontinued tapentadol therapy, i.e. 37% due to adverse effects, 15% because of inadequate pain management, and 2% because of a negative attitude of their primary care physician. Our study confirmed the efficacy of pain management with tapentadol. The total adverse effect rate was comparable to reports found in the literature and was lower than with classical opioid therapy. A relatively high therapy discontinuation rate was noted primarily due to adverse effects.
- Subjects
PAIN management; OPIOID receptors; PAIN clinics; VISUAL analog scale; CHRONIC pain
- Publication
Acta Medica Croatica, 2019, Vol 73, Issue Suplement 1, p23
- ISSN
1330-0164
- Publication type
Article